Lipocine is trading 5.04% lower at $1.60 in pre-market on October 15, versus its October 14 close of $1.69; broader risk-off conditions may be contributing, though a direct link is unconfirmed. - No new company-specific announcement explaining the move was identified; the latest located company news was Health Canada’s TLANDO approval on October 7. - Risk-off conditions followed hotter-than-expected U.S. inflation, with Asian markets sharply lower and Nasdaq futures also down.